Authors
Trond V Bogsrud, Dimitrios Karantanis, Mark A Nathan, Brian P Mullan, Gregory A Wiseman, Douglas A Collins, Jan L Kasperbauer, Scott E Strome, Carl C Reading, Ian D Hay, Val J Lowe
Publication date
2007/5/1
Journal
Nuclear medicine communications
Volume
28
Issue
5
Pages
373-381
Publisher
LWW
Description
Objective
To determine if quantification of [18 F] fluorodeoxyglucose (18 F-FDG) uptake in a thyroid nodule found incidentally on whole-body 18 F-FDG positron emission tomography–computed tomography (PET–CT) can be used to discriminate between malignant and benign aetiology.
Methods
A retrospective review of all patients with focally high uptake in the thyroid as an incidental finding on 18 F-FDG PET–CT from May 2003 through May 2006. The uptake in the nodules was quantified using the maximum standardized uptake value (SUV max). The aetiology was determined by cytology and/or ultrasound, or on histopathology.
Results
Incidental focally high uptake was found in 79/7347 patients (1.1%). In 31/48 patients with adequate follow-up, a benign aetiology was determined. Median SUV max for the benign group was 5.6, range 2.5–53. Malignancy was confirmed in 15/48 patients. The malignancies were …
Total citations
Scholar articles
TV Bogsrud, D Karantanis, MA Nathan, BP Mullan… - Nuclear medicine communications, 2007